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Abstract
Background: The use of lLaparoscopic liver resection in terms of time to functional recovery, length of hospital stay
(LOS), long-term abdominal wall hernias, costs and quality of life (QOL) has never been studied in a randomised
controlled trial. Therefore, this is the subject of the international multicentre randomised controlled ORANGE II trial.
Methods: Patients eligible for left lateral sectionectomy (LLS) of the liver will be recruited and randomised at the
outpatient clinic. All randomised patients will undergo surgery in the setting of an ERAS programme. The
experimental design produces two randomised arms (open and laparoscopic LLS) and a prospective registry. The
prospective registry will be based on patients that cannot be randomised because of the explicit treatment
preference of the patient or surgeon, or because of ineligibility (not meeting the in- and exclusion criteria) for
randomisation in this trial. Therefore, all non-randomised patients undergoing LLS will be approached to participate
in the prospective registry, thereby allowing acquisition of an uninterrupted prospective series of patients. The
primary endpoint of the ORANGE II trial is time to functional recovery. Secondary endpoints are postoperative LOS,
percentage readmission, (liver-specific) morbidity, QOL, body image and cosmetic result, hospital and societal costs
over 1 year, and long-term incidence of incisional hernias. It will be assumed that in patients undergoing
laparoscopic LLS, length of hospital stay can be reduced by two days. A sample size of 55 patients in each
randomisation arm has been calculated to detect a 2-day reduction in LOS (90% power and α= 0.05 (two-tailed)).
The ORANGE II trial is a multicenter randomised controlled trial that will provide evidence on the merits of
laparoscopic surgery in patients undergoing LLS within an enhanced recovery ERAS programme.
Trial registration: ClinicalTrials.gov NCT00874224.
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Background
Liver resection for colorectal metastasis is the only poten-
tially curative therapy, and has become the standard of
care in appropriately staged patients, offering 5-year sur-
vival rates of approximately 35-40% [1]. For symptomatic
benign lesions and those of uncertain nature or large size,
liver resection is also a widely accepted treatment. Within
the framework of optimising postoperative recovery and/
or producing a shorter length of stay (LOS) in hospital,
laparoscopic surgery and enhanced recovery programmes
have recently been introduced for liver surgery.
Laparoscopic liver resection was first described in 1995
[2]. Over the past decade the method has gained wide ac-
ceptance for various liver resection procedures [3-9]. Mul-
tiple retrospective case series and reviews comparing open
with laparoscopic liver resection indicate that laparoscopic
liver resection can be used safely for both malignant and
benign liver lesions [10-15]. Recent publications from ex-
pert centers show that a substantial part of the total vol-
ume of major and minor liver resections is performed
laparoscopically, and results are good [16,17]. Laparo-
scopic liver resection is associated with shorter LOS, less
postoperative pain, earlier recovery, and better quality of
life (QOL) [9,13,18,19]. Comparing patients undergoing
an open left lateral sectionectomy (LLS) of the liver with
those undergoing laparoscopic LLS, both Vigano et al.
and Carswell et al. [20,21] found no significant difference
in operating time between the two groups. In addition,
the median length of postoperative LOS was significantly
less (6 vs. 9 days, P < 0.01) after laparoscopic resection
[3]. Furthermore, no evidence of a compromised oncolo-
gic clearance in laparoscopic liver resection has been
found [3,13]. However, recovery and LOS are not only
dependent on the type of surgery or procedure, and other
variables should also be taken into account.
The Enhanced Recovery After Surgery (ERAS)
programme has been introduced to improve postoperative
care. This multimodal programme, derived from Kehlet’s
pioneer work in the 1990s for multimodal surgical care,
involves optimisation of several aspects of the periopera-
tive management of patients undergoing major abdominal
surgery. In patients undergoing segmental colectomy, the
ERAS programme enabled earlier recovery and conse-
quently shorter LOS [22-25]. Furthermore, a reduction of
post-operative morbidity in patients undergoing intestinal
resection was reported [26-29]. These results stimulated
liver surgeons of the ERASW group (Maastricht, Edinburgh
and Tromsö) to adapt the ERAS programme to patients
undergoing open liver resection. Van Dam et al. [30] found
a significantly reduced LOS after open liver resection when
patients were managed within a multimodal ERAS
programme. Besides a reduction in median total LOS from
8 to 6 days (25%), the data also suggested that a further re-
duction in stay could be possible as there was a delay
between the recovery and actual discharge of the patients
[30]. Moreover, Stoot et al. found retrospectively that there
was a further reduction in LOS from 7 days to 5 days when
patients were operated laparoscopically and managed
within an ERAS programme [31]. In that study there was
also a delay between recovery and actual discharge of the
patients. Previously, Maessen et al. reported a median
delay to discharge of 2 days after patients had functionally
recovered after colonic surgery managed within an ERAS
programme [32]. This delay is often linked to patient age,
hospital logistics, and absence of social and/or homecare
support.
In most reported trials aiming at earlier recovery or a re-
duction in LOS, type of surgery and/or perioperative man-
agement were not standardised. In addition, the added
value of laparoscopic LLS compared with open left lateral
sectionectomy within an ERAS programme in terms of
time to functional recovery, LOS in hospital, costs, and
QOL has never been studied in a randomised controlled
trial (RCT). However, randomisation of patients undergo-
ing open or laparoscopic liver resection is hazardous. It is
to be expected that experienced centres will be reluctant
to randomise patients because of the absence of clinical
and patient equipoise for laparoscopic resection. To capit-
alise on both centers with and without preference for lap-
aroscopic liver surgery, and to thereby acquire an
uninterrupted prospective series of patients, an alternative
trial design with two randomisation arms (open versus lap-
aroscopic surgery) and a prospective registry has been con-
structed for the ORANGE II trial. The combination of an
RCT and a prospective registry will improve overall power
and strengthen the external validity and generalisability of
study results [33-35].
Methods
Ethics approval
The study has been approved by the Medical Ethical
Review Board of the Maastricht University Medical
Center, Maastricht, The Netherlands trial number NL
25591.068.08 / MEC 08-2-110. Ethics consent will also
be obtained from the national or regional ethics boards in
each participating country. Patients willing to participate
in this trial will receive both verbal and written informa-
tion at the time of recruitment in the outpatient clinic. In
accordance with the local medical ethics committee all
participating sites will provide an independent surgeon or
physician if needed. An independent surgeon (M. Poeze)
has been appointed for the Maastricht University Medical
Center to answer questions. Confidentiality is guaranteed
by assigning the participators an encoded trial number.
This indicates that only the physician with the decoding
‘key’ will know which code number has been assigned to
any patient. All trial data will be saved during the trial and
stored on a server, and patients will be asked to consent to
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future analysis of these data. Withdrawal from the trial at
any time or for any reason will not hold any form of conse-
quences for the patient, and data from these patients will
be deleted.
Study design
The ORANGE II trial is a prospective superiority study
with an experimental design, using two double-blinded
randomised controlled arms and a prospective registry to
determine whether laparoscopic surgery is to be pre-
ferred over open surgery in patients undergoing a LLS
and participating in an enhanced recovery programme.
In the participating randomising centers, patients, nurses
and the ward physician (but not the operating surgeon)
will be blinded for the type of intervention up to and in-
cluding postoperative day (POD) 3. They will record the
functional recovery criteria twice daily. Only the investi-
gator and operating surgeons will know the actual pro-
cedure. The blinded ward physician(s) will decide on
whether a patient will be discharged or not.
However, randomisation of patients undergoing open
or laparoscopic liver resection is hazardous as previously
explained. Moreover, another potential source of bias
exists when randomising patients with a strong treat-
ment preference. When patients cannot be blinded to
their treatment allocation (POD 3) they may be resentful
and demoralised if they do not receive their preferred
treatment, and consequently they may have poor compli-
ance. By contrast, patients receiving their preferred treat-
ment may have above-average compliance.
Thus to capitalise on centres both with and without
preference for laparoscopic liver surgery, and thereby to
acquire an uninterrupted prospective series of patients,
all non-randomised patients undergoing a LLS will be
approached to participate in the prospective registry.
Registration of these patients is imperative to guarantee
a consecutive series of patients and also because the ab-
sence of such a series may restrict generalisation of the
results, as randomised participants may not in fact be
representative [36]. The combination of an RCT and a
prospective registry will improve overall power and
strengthen the external validity and generalisability of
study results [33-35]. This non-randomised registry
group will be analysed for centre and centre by treat-
ment interaction as an observational study. Medical cen-
tres that wish to participate in this trial, but with liver
surgeons early in the laparoscopic learning curve, will be
accompanied during the procedure by an experienced
proctoring laparoscopic HPB-surgeon.
Primary & secondary endpoints
The primary endpoint of the ORANGE II trial is time to
functional recovery. A patient is fully functionally recov-
ered when all of the following five criteria are satisfied:
1) adequate pain control with oral analgesia; 2) restor-
ation of mobility to an independent level; 3) absence of
intravenous fluid administration; 4) ability to eat solid
foods; and normal or decreasing serum bilirubin level
and international normalised ratio.
It is medically justified to discharge patients when the
criteria for full functional recovery are met and if the
patient is willing to go home. Secondary endpoints in-
clude postoperative LOS in hospital, percentage of read-
missions, total morbidity (both general and procedure
related), composite endpoint of liver-surgery-specific
morbidity, QOL, body image and cosmesis, reasons for
delay of discharge after functional recovery, hospital and
societal costs over 1 year, and long-term incidence of in-
cisional hernias.
Morbidity
The preoperative morbidity status of patients will be
measured using the American Society of Anesthesiolo-
gists (ASA) scale. The Portsmouth modification of the
Physiological and Operative Severity Score for the Enu-
meration of Mortality and Morbidity (P-POSSUM) will
be used to evaluate the risk of perioperative morbidity
and mortality. Post-operative morbidity is rationally
predictable, with hemorrhagic complications occurring
predominantly during surgery or in the early postopera-
tive phase, and biliary complications, intra-abdominal
abscess, or liver failure in the later postoperative phase.
Wound infection and sepsis will be additional complica-
tions that require monitoring. Morbidity will be classi-
fied and analysed according to the validated
classification for postoperative morbidity as described
by Dindo et al [37].
Liver resection-specific composite endpoint
In this trial, we will also use a well-defined liver surgery-
specific composite endpoint, as suggested by van den
Broek et al. [38]. This endpoint is a parameter composed
of a combination of procedure-specific complications,
which is considered as a single, dichotomous outcome:
operative mortality, intra-abdominal haemorrhage, asci-
tes, bile leakage, intra-abdominal abscess, and post-resec-
tional liver failure. These components, which are all
specific to liver surgery and have substantial clinical rele-
vance, reflect complications rated as Dindo grade 3–5. A
composite score of 1 (failure) will reflect the occurrence
of at least one of the above liver-specific complications,
and a score of 0 (success) will be assigned if none of
these occur.
Quality of life
To assess QOL in patients undergoing laparoscopic ver-
sus open LLS, the Dutch version of the EuroQol five-
dimension (EQ-5D) status test in Dutch centers and the
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translated EQ-5D for international centers will be used.
The EQ-5D is a standardised instrument for use as a
measure of health outcome, which consists of the five
dimensions of mobility, self-care, usual activities, pain/
discomfort, and anxiety/depression, with three levels
each and a rating on the EQ visual analogue scale
(VAS; 0–100). [39-41] Furthermore, the European Or-
ganisation for Research and Treatment (EORTC) 30-
item post-cancer QOL questionnaire (QLQ-C30; with
the liver metastases (LM21) module will be used for
liver-specific treatment measurements [42]. Assessment
of the patients’ QOL will be performed at the time of
consent, discharge and 10 days, 3, 6 and 12 months after
discharge.
Body image and cosmesis
To evaluate differences in postoperative body image and
cosmesis, the Body Image Questionnaire (BIQ) will be
used [43,44], which consists of eight questions about
body image and cosmesis. The body image assessment
will be performed preoperatively at time of consent. Both
the body image and cosmesis assessment will take place
at discharge, and at 10 days, 3 months, 6 months and 12
months after discharge.
Hospital and societal costs
The economic evaluation will include a cost-utility ana-
lysis from a Dutch societal perspective. The incremental
costs per quality adjusted life year (QALY) gained will
be based on utility scores from the EQ-5D [39-41]. All
hospital expenses (direct and indirect) related to both
interventions will be monitored. In addition, a cost
questionnaire offered at the regular follow-up consult-
ation (3, 6 and 12 months) will help assess the societal
and individual costs outside health care relating to
patients’ absence, impaired mobility, work, or normal
daily activities. Unit prices will be based either on
prices from the participating hospital financial depart-
ments or will be extrapolated using Dutch guidelines
for cost calculation [45].
Incidence of incisional hernias
Incisional hernia after open surgery is a well-known
complication of surgery, with an incidence of up to 20%
after a 10-year period [46]. In patients undergoing a sig-
moid resection, Anderson et al. found that laparoscopic
resection led to a significantly lower incidence of inci-
sional hernia compared with open surgery [47]. Further-
more, in two retrospectively analysed series of patients
who received a partial hepatectomy, different types of
incisions were compared. D’Angelica et al. reported that
the common incisions used for partial hepatectomy were
the Mercedes incision and extended right subcostal
(ERSC) incision, and that the ERSC incision provides
adequate, safe access and is associated with fewer long-
term wound complications (9.8% vs 4.8%, P< 0.001)
[48]. More recently, Togo et al. reported frequencies of
incisional hernia after median, J-shaped, right transverse
incision with a vertical extension at the midline from the
subumbilical region to the xiphoid process (RTVE), and
reversed T incisions to be 6.3%, 4.7%, 5.4%, and 21.7%,
respectively. A diagnosis of ‘no hernia’ required a mini-
mum follow-up of 12 months [49].
To assess the incidence of incisional hernias in patients
undergoing laparoscopic and open LLS, they will be con-
tacted at a mean time of 1 year after resection to undergo
ultrasonography to assess the incidence of incisional
hernia.
Study population
Every patient requiring an LLS will be identified and
informed at the outpatient clinic about open and laparo-
scopic liver resection. Only patients meeting the inclusion
and exclusion criteria will be approached for randomisa-
tion. After reading the ORANGE II trial patient informa-
tion and being allowed 1 week for consideration, patients
will be asked for their informed consent. All patients ineli-
gible for randomisation will be approached for participa-
tion in the prospective registry. If patients express an
explicit preference, they will be allocated to the prospect-
ive registry and interviewed to ascertain the reasons for
their preferences. Personal written informed consent will
be obtained for all groups. Randomisation will be carried
out through the ORANGE II trial website using web-
based randomisation software (TENALEAW; www.tenalea.
com) (see Figure 1 for trial flow-chart).
Patients will be approached for randomised inclusion if
they meet each of the following inclusion criteria: require
LLS; willingness to participate in the study; able to
understand the nature of the study and what will be
required of them; are men or non-pregnant, non-lactat-
ing women between the ages of 18 and 80 years of age;
have a body mass index of between 18 and 35; and have
ASA grading of I to III.
The exclusion criteria are: liver resection other than LLS;
underlying liver disease; unwillingness to participate; in-
ability to give written informed consent; and ASA grading
of IV to V.
ERAS-programme
All patients will participate in the ERAS liver programme,
with a standardised peri-operative management. For daily
guidelines of the pre- and postoperative care of patients
undergoing liver resection (Figure 2).
Functional recovery criteria
The evaluation of time to functional recovery will start on
POD 0 and will be scored twice daily until discharge from
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the hospital. The discharge process starts at the pre-admis-
sion counseling session, during which any special needs of
the patients will be determined (for example, homecare or
social support, transport. Before admittance, any problem
that could delay discharge will be identified and addressed.
Patients will only be discharged when they have met the
functional recovery criteria and are willing to go home.
Reasons to delay discharge after functional recovery will
be monitored and documented. Functional recovery cri-
teria and LOS in hospital will be independently monitored
and analysed.
Adequate pain control with oral analgesics
Postoperative pain will be systematically registered twice
daily using the validated verbally administered 11-point
numeric rating scale (NRS-11, 0 to 10) [50-53]. Members of
a specialised pain team will ask patients to rate the intensity
of their current pain on a scale of 0 (no pain) to 10 (worst
possible pain), with pain rated as ‘mild’ (1 to 3) ‘moderate’
(4 to 6) or ‘severe’) 7 to 10 [54]. The NRS-11 seems to be
better accepted by most patients and to be at least as sensi-
tive and valid as the more traditional VAS ratings [53].
Tolerance of solid food
Fluid and solid food intake will be monitored and must
return to normal, that is, when oral intake of water or
normal food is resumed and continued for at least 24
hours. Furthermore the incidence of postoperative nau-
sea and vomiting, which obviously influences intake, will
be monitored postoperatively until day 6 using a scale
Figure 1 Orange II-Trial Flowchart.
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ranging from 0 (no nausea) to 10 (worst possible nau-
sea), and where necessary, be countered prophylactically
by antiemetic treatment.
Mobility
To assess the difference between the preoperative and
postoperative mobility level, the ERAS Mobility Scale
(EMS) has been developed from the Groningen Activity
Restriction Scale [55]. The EMS assesses 10 basic actions
to compare the level of mobility before and after surgical
intervention. When the patient is able to perform 8 of
the 10 items, they are independently mobile. Patients will
be assessed whether they are able or not to independently
perform these basic actions fully. Daily the assessment
will be repeated and compared with the preoperative
baseline score until mobility at an independent or pre-
operative level is achieved.
Statistical analysis
Sample size
Because laparoscopic liver surgery focuses on accelerated
recovery, time to functional recovery is used as the
primary outcome parameter. Owing to the lack of hard
evidence about the reduction in time to functional recov-
ery after liver surgery, we have chosen to use the param-
eter that most accurately approaches our primary
endpoint for our power calculation (LOS). Based on a
retrospective analysis of 31 patients in both ERAS and
non-ERAS settings, who have undergone LLS from 1990
to the present time, the mean ± SD post-operative hos-
pital stay for a LLS in the Maastricht University Medical
Center is 6 ± 2.73. It therefore seems that that in
patients undergoing laparoscopic LLS, time to functional
recovery is reduced in comparison to patients undergo-
ing the open procedure. We are aiming for a reduction
in time to functional recovery of 2 days. A sample size of
2 × 40 patients in the randomisation arms will be suffi-
cient to show a 2-day reduction with a power of 90% and
a level of significance at α = 0.05 (two-tailed, given a
within-arm SD of 2.73 with effect size d = 0.73). Assum-
ing an expected withdrawal rate of ≤ 10% during the
trial, the participation of at least 10 centres, and the
required addition of one randomised patient per arm for
every additional participating centre (C) to compensate
Figure 2 Daily guideline of postoperative care of patients undergoing a hepatectomy in the ERAS programme.
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for the loss of degrees of freedom incurred in the data
analysis, which takes centre and treatment × centre
effects into account, a total sample size of 110 (n = 2 ×
55) will be required.
For all secondary outcome measures, the power will be
75% after correction for multiple testing with two-tailed
α= 0.01, assuming the same effect size (d= 0.73) as for
the primary outcome. An interim analysis of the primary
outcome, using Snapinn’s method, will be performed
after inclusion of 50% of the sample to avoid unnecessary
inclusion of too many patients in this ORANGE II trial
[56].
Descriptive statistics
The primary outcome parameter of time to functional re-
covery and the secondary parameter of LOS in hospital
will be given in days, with a median and range. Morbidity
will be classified according to the classification described
by Dindo et al. and defined as a dichotomous composite
endpoint, while readmission will be given as a percentage.
Scores for quality of life, body image and cosmesis will be
given as mean and standard deviation per time point per
treatment arm. Hospital costs will be given as median and
range. Long-term incidence of incisional hernia will be
reported and analysed.
Univariate analysis
The primary outcome measure of time to functional re-
covery will be measured in days, and will be analysed
with fixed-effect regression that will take centre and
treatment × centre interaction into account as fixed
effects. If the actual number of centers and the sample
size per centre allow random effects analysis, this will
also be performed and this analysis will have the same
power as the planned fixed effects analysis if the design
effect does not exceed 1.2. With a sample size of 10
patients per centre, the design effect is 1.2 if the intra-
class correlation (ICC) is 0.02, where the ICC is based
on treatment × centre interaction [57].
All secondary outcomes as measured at discharge will be
analysed by fixed-effect regression using linear regression
for quantitative outcomes and logistic regression for binary
outcomes, and including the baseline measure as a covari-
ate to improve power and precision. In addition to P-
values, confidence intervals for all effects will be reported.
Morbidity will be classified as described by Dindo et al.,
but will be presented as raw data only because the required
sample size for intervention effects on morbidity is much
larger than the calculated sample size for this trial [58].
Economic evaluation
The economic evaluation will include a cost-utility ana-
lysis from a societal perspective. The time horizon of this
evaluation will be the same as the duration of the trial,
that is, 12 months. All costs (direct and indirect) related
to both interventions will be calculated. The final cost
calculation of unit costs will be based on a combined
bottom-up and top-down approach. In accordance with
Dutch guidelines for cost calculation, indirect healthcare
costs will not be taken into account. In addition, re-
source use will be measured by use of primary data that
is registered in our case record forms (CRFs) by use sim-
ple checklists. Furthermore, a questionnaire will be used
to survey the direct non-healthcare costs related to trav-
elling, impaired mobility and domiciliary care (for nor-
mal daily activities). The incremental, indirect non-
healthcare costs per QALY gained will be based on the
utility scores from the EQ-5D [39-41]. For all direct
healthcare costs, the unit prices will be based either on
prices from the hospital financial department or the
Dutch guidelines for cost calculation [45].
Registry
The prospective registry of patients who cannot be rando-
mised because of ineligibility or because of explicit treat-
ment preference on the part of the patient or surgeon will
be analyzed as an observational study. In addition, data
from the registry will be analyzed for interaction between
treatment, centre, and study type (randomised or not). On
condition that there is no interaction between treatment,
centre, and study type, and that the observational study
does not suffer from severe confounding (because adjust-
ing for that strongly reduces the power of the observa-
tional study), pooling of both studies should give more
power than separate analyses of either study. Possible con-
founders will be registered in the CRFs. The inclusion of
the prospective registry in the trial design will create an
uninterrupted case series, which will increase external val-
idity and generalisability.
Data collection
Data concerning patient characteristics, functional recov-
ery, surgical and anaesthesiologic parameters, morbidity,
LOS, QOL, patient compliance, and costs will be pro-
spectively collected using both paper CRFs and an open
source clinical trial software platform (OpenClinicaW;
Ikaza Research, Cambridge, MA, USA) that uses e-CRFs
for electronic data capture and clinical data manage-
ment, which are validated and stored in compliance with
good clinical practice guidelines. The e-CRFs will be
stored in a secured database (Oracle Cor., Redwood
Shores, CA, USA), and as stated previously, all patient
data will be encoded to ensure privacy.
Monitoring
For this trial, a Data and Safety Monitoring Board
(DSMB) has been appointed that will consist of three
members: a chairperson, an independent statistician, and
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a medical specialist. In a concerted effort a DSMB char-
ter will be developed, and all three members will sign a
non-competing interest form. The DSMB will be respon-
sible for safeguarding the interests of trial participants,
assessing the safety and efficacy of the interventions dur-
ing the trial, and monitoring the overall conduct of the
clinical trial.
Intention to treat
Analysis of all patients will be performed according to
the intention-to-treat principle: patients will be analysed
as randomised or as planned in the non-randomised pro-
spective registry, and all patients will be included in the
data analysis with proper methods for handling missing
data.
Discussion
Several authors have indicated that laparoscopic liver re-
section has many benefits over conventional open liver re-
section. However, this has never been proven in an RCT,
and what the primary endpoint should be for an RCT
comparing open and laparoscopic liver resection is a sub-
ject to debate. Using either liver surgery-related mortality
or liver surgery-specific morbidity as an endpoint is not
feasible, because patient accrual would take many years
and be a logistically major global effort [58]. LOS in hos-
pital, time to recovery, long-term incisional hernias, body
image, and costs are potential candidates because improve-
ments in these are some of the possible benefits. Laparo-
scopic liver resection is appealing for many surgeons and
patients, but the learning curve for the surgeon is thought
to be long and costly for hospital budgets. However, oper-
ating times in laparoscopic LLS tend to be shorter, and
may compensate for expenses in technology and consum-
ables [31,59]. Moreover, the existing trials in liver surgery
have not evaluated time to recovery or LOS in hospital
after laparoscopic liver resection within an enhanced re-
covery programme. The more rapid recovery reported
after enhanced recovery programmes may be further accel-
erated as a consequence of small incisions in laparoscopic
surgery. In addition, learning curves for laparoscopic left
lateral resection or anterior segments seem to be reason-
ably short for liver surgeons with advanced laparoscopic
experience [60]. The question remains whether an RCT is
necessary to prove that laparoscopy should be accepted as
the preferred method to perform liver resection. In the
Louisville consensus meeting on laparoscopic liver surgery,
it was stated that laparoscopic LLS should be standard
practice in experienced hands [61]. However, this may
have been a subjective vision of a subset of opinion leaders,
because long experience with both open and laparoscopic
liver surgery was the main characteristic of those attending
the meeting. Undoubtedly, the dissemination phase of lap-
aroscopic liver surgery has started, and it is to be expected
that many surgeons will adopt this technique in the future.
A multinational multicentre prospective registry, a well-
organised multicentre RCT, training programmes, and
quality control measures are of great importance during
this adoption period [33].
It is well recognised that a well-conducted double-blind
RCT provides the highest level of evidence to prove the
possible benefits of laparoscopic liver resection. However,
performing an RCT in surgery is not without difficulties,
and alternative trial designs may be necessary [33,34,62].
First, the intervention needs to be tested in a standardised
environment, and the properties of the intervention should
remain unchanged during the trial period. This seems im-
possible for an intervention such as laparoscopic liver sur-
gery in a multicentre RCT. Experience varies between
participating centres, and will vary over time. Moreover,
local standards for perioperative care are different. Both
LLS and the ERASW enhanced recovery protocol provide
the standardisation needed. The learning curve of a LLS is
short in centres with experience in liver surgery and
advanced laparoscopy. The use of proctor surgeons in cen-
tres with limited experience in laparoscopic liver surgery
the operative techniques can be reasonably standardised,
and this should eliminate learning curve influences on out-
come parameters. Quality of the surgery can be assured by
digital video recording.
Second, the intervention should be double-blinded. Al-
though double blinding in a surgical trial is difficult,
using a fixed abdominal dressing for 3 days after surgery
is feasible, and should prevent both ward caregivers and
patients from knowing the type of intervention.
Third, it is reasonable to query whether this is now the
right time to perform an RCT and whether the results of
the trial will be valid for the more general surgical commu-
nity. A recent review of the results of laparoscopic liver re-
section in 2,804 patients showed that laparoscopic liver
resection in expert centres is feasible and safe for both
minor and major liver resections [36]. The percentages of
liver resections performed laparoscopically now range
from 25% to 65% in high-volume expert centres such as
University Hospital Southampton NHS (Southampton,
UK), Henri Mondor (Paris, France), UPMC (Pittsburgh,
USA), UZ Leuven (Leuven, Belgium) and Rikshospitalet
(Oslo, Norway) [36,63]. Although it is to be expected that
many centres worldwide will adopt laparoscopic liver re-
section as a more or less standard procedure in the near
future, there are still many patients and surgeons that pre-
fer the open procedure long beyond the learning curve. In
parallel with the development of laparoscopic liver surgery,
‘fast-track’ programmes in various areas of surgery, includ-
ing liver surgery, are gaining popularity. Therefore, this
seems to be the right time for this RCT to be performed.
The multicentre character of the ORANGE II trial with
randomisation of patients and surgeons with treatment
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equipoise and a prospective registry to cover both sur-
geons who believe that based on their laparoscopic experi-
ence randomisation is not ethically justified and patients
with a strong treatment preference will provide external
validity. This trial design capitalises on rather than ignores
the differences between patients, will provide more robust
outcome data, and should lead to continuous performance
monitoring after the trial [35,62].
The key question clearly is as to whether this RCT is
really necessary. The benefits of laparoscopic liver resec-
tion are not beyond reasonable doubt, and although data
are becoming increasingly available, recent publications
do not provide sound data on time to recovery. World-
wide, median LOS in hospital for open and laparoscopic
resections varies from 4 to 8 days [17,30,64-66]. Reasons
for delay in discharge and discharge location are often
absent, and a clear definition of recovery has not been
used to date in any of the publications. Departing from
the standpoint that an RCT should be conducted, the
question is which sample size should be used? In our
opinion, a reduction of only 1 day in time to recovery or
LOS in hospital after laparoscopic resection would be a
disappointingly low gain. To prove such a reduction, 320
patients would be needed (α = 0.05 and power of 90%),
making the trial unlikely to be accomplished. Based on
available reports, a 2-day reduction should be possible
[17,31,66], and reduces the sample size to 110 patients
undergoing LLS. This number is reasonably moderate,
and it is to be expected that patient accrual will be
accomplished within 1–2 years.
It should be realised that many centres have intro-
duced laparoscopic liver surgery programmes in the ab-
sence of a central reporting or certifying agency. In our
opinion, laparoscopic LLS should function as a model
for further dissemination of laparoscopic techniques in
hepatic surgery. The left lateral segment of the liver has
been a natural first step for a laparoscopic resection
given the peripheral anatomical location (thin liver seg-
ment, minimal requirement for biliary dissection, and
ease of controlling the left portal pedicles and left hep-
atic vein), and has been proven to be safe and feasible
with reproducible results [20,36]. The implementation of
the laparoscopic LLS may not only serve as a guide to
develop and master programmes for major laparoscopic
hepatic resections, but may also be used as an introduc-
tion for centres new to laparoscopic approaches in liver
surgery. To adopt laparoscopic liver resection safely, cer-
tification for centres, surgeons, and units should be avail-
able through the International Hepatobiliary (HPB)
Association, and national and international HPB associa-
tions should become involved in the goal of establishing
training standards and credentials to ensure a high and
consistent outcome. The ORANGE II trial in which
techniques are standardised and a training and proctor
programme is available, combined with the hybrid design
of randomisation and registry may help to provide a
framework for controlled and safe implementation of
laparoscopic liver resection across participating centres.
Conclusions
The international multicentre randomised controlled OR-
ANGE II trial is based on the observations of more rapid
recovery and discharge after laparoscopic liver resection,
and more rapid recovery and discharge after open liver re-
section within an enhanced recovery programme. This is
the first RCT to provide evidence on the merits of laparo-
scopic surgery in patients undergoing a LLS within an
enhanced recovery programme.
Trial status
Currently there are nine actively participating centres, con-
sisting of the Maastricht University Medical Center
(MUMC), Academic Medical Center (AMC), University
Medical Center Utrecht (UMCU), Erasmus Medical Cen-
ter (Erasmus MC), University Medical Center Groningen
(UMCG), Maxima Medical Center (MMC), Medical
Spectrum Twente (MST) in The Netherlands. In addition,
the University Hospital Aachen (UK Aachen) and San Raf-
faele Hospital Milan (HSR Milan) are two participating
centres in Germany and Italy. Additional centres will be
invited to participate.
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